DXS - the K-RAS company

DxS is a personalised medicine company and leader in the provision of molecular diagnostics. Working predominantly in the field of cancer, it has developed a range of companion diagnostic and research kits which can be used to detect mutations in oncogenes associated with drug response.

Last year saw DxS work closely with Amgen Inc as they selected the DxS TheraScreen^®: K-RAS test as the companion diagnostic for assessing a patient's KRAS mutation status. For approximately 40% of patients with a mutated K-RAS gene, treatments such as Amgen's Vectibix^® for colorectal cancer are not effective. DxS was able to secure a deal with Amgen to provide TheraScreen® as a companion diagnostic for Vectibix following the EMEA's decision to approve Vectibix on the condition that it was provided with a companion diagnostic. The success of this across Europe led DxS to appoint Roche Diagnostics as its global distributor of the K-RAS test. DxS also inked a further agreement with Amgen to offer the K-RAS test as a diagnostic in the USA and the two companies are working closely with the FDA to deliver this for assay on the market for US patients.

• Raise awareness of DxS and the effectiveness of its assays as companion diagnostics
• Increase the profile of DxS as a leader in the field of companion diagnostics

Our Approach

• Pre-briefing select media on DxS and the current landscape around the FDA and companion diagnostics. Pre-briefed media included Clinica, Dow Jones, Financial Times and Pharma Marketletter
• Extensive media follow up around a release announcing Amgen and DxS had entered into a collaboration to get Amgen approved for use with DxS' companion diagnostic

• Coverage achieved following news announcement in a wide range of publications, including BioCentury, Pharmacogenomics Reporter, GEN, Clinica, Pharma Marketletter, Scrip, Dow Jones, APM Health, Genome Web, Laboratory Talk and Manchester Evening News
• Feature articles on DxS and companion diagnostics also appeared in Clinica and Pharma Marketletter

Joanne Cross, Marketing Manager at DxS said: "This was very big news for DxS, and it was important that it was properly communicated. College Hill did a great job in helping DxS get a complicated message across to the right media."

January 2009

To discuss our capability in this area please contact:
Sue Charles, Managing Partner
+44 (0)207 457 2020
sue.charles[at]collegehill.com

© 2012 College Hill Associates | Registered in England No 1036926 / VAT No 245666930 | Legal

other clients